Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Tonsillar Neoplasms × Dermatologic × Clear all
NCT03602079 2023-08-03

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Klus Pharma Inc.

Phase 1/2 Completed
49 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Bile Duct Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Head and Neck Neoplasms, Laryngeal Neoplasms, Lip Neoplasms, Liver Neoplasms, Lung Neoplasms, Mouth Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Skin Neoplasms, Stomach Neoplasms, Tongue Neoplasms, Tonsillar Neoplasms, Urologic Neoplasms, Carcinoma, Mucoepidermoid, Cholangiocarcinoma, Rare Diseases